| SESSION HIGHLIGHTS | |||
|---|---|---|---|
| Time in Hrs (IST) | Track Code | Topics and Session Tracks | |
| GBR - 1 | |||
| 08:00 - 10:00 | Pre Conference Workshop - 1 | Postgraduate Exam Bootcamp: Skills, Strategy & Success | |
| 10:00 - 11:40 | Scientific Session | Track: Breast Cancer - Metastatic | |
| 12:05 - 13:25 | Scientific Session | Track: Breast Cancer - Local/Regional/Adjuvant | |
| 14:05 - 15:30 | Scientific Session | Track: Head & Neck | |
| Session 01 | Track: (i) Breast Cancer - Metastatic | |||
|---|---|---|---|
| Chairperson: TBD | |||
| Time in Hrs (IST) | Track Code | Paper ID | Topic |
| 10:00 – 11:10 | MBC Plenary (10 Mins) |
LBA4 | Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. |
| MBC (5 Mins) |
1001 | Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial. | |
| MBC (5 Mins) |
1003 | "INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)." | |
| MBC (5 Mins) |
1009 | Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial) | |
| MBC (5 Mins) |
1013 | Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINYBreast06 (DB-06) | |
| MBC (5 Mins) |
1015 | Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study. | |
| MBC (5 Mins) |
1030 | Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort. | |
| MBC (5 Mins) |
1039 / 1040 | Risk of radiation necrosis with concurrent antibody-drug conjugates and radiotherapy in HER2-positive breast cancer with brain metastases: A metaanalysis. / Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC). | |
| MBC (5 Mins) |
LBA1000 | Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. | |
| MBC (5 Mins) |
LBA1005 | A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581). | |
| MBC (5 Mins) |
LBA1008 | Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09. | |
| MBC (5 Mins) |
LBA109 | Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. | |
| MBC (5 Mins) |
TBD | ||
| 11:10 - 11:20 | IT (10 Mins) |
Invited Talk | |
| Moderators: TBD | |||
| 11:20 - 11:40 | PD (20 Mins) |
Panel Discussion: Track: (i) Breast Cancer—Metastatic | |
| 11:40 - 11:50 | IS (TBD) (10 Mins) |
Industry Session by TBD: Topic TBD | |
| 11:50 – 12:05 | Tea Break (20 Mins) |
Tea Break | |
| Session 02 | Track: (i) Breast Cancer—Local/Regional/Adjuvant | |||
| Chairperson: TBD | |||
| 12:05 - 12:55 | LABC (5 Mins) |
501 | Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial. |
| LABC (5 Mins) |
504 | Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial. | |
| LABC (5 Mins) |
505 | 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS. | |
| LABC (5 Mins) |
507 | The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study. | |
| LABC (5 Mins) |
508 | Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial. | |
| LABC (5 Mins) |
511 | A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. | |
| LABC (5 Mins) |
521 | The effect of endocrine therapy omission on survival in ER-negative PR-low (1–10%) early-stage breast cancer treated with chemotherapy. | |
| LABC (5 Mins) |
LBA500 | De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial. | |
| LABC (5 Mins) |
LBA509 | NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC. | |
| LABC (5 Mins) |
TBD | ||
| 12:55 - 13:05 | IT (10 Mins) |
Invited Talk | |
| Moderators: TBD | |||
| 13:05 - 13:25 | PD (20 Mins) |
Panel Discussion: Track: (i) Breast Cancer—Local/Regional/Adjuvant | |
| 13:25 - 13:35 | IS(TBD) (10 Mins) |
Industry Session by TBD: Topic TBD | |
| 13:35 - 14:05 | Lunch Break (30 Mins) |
Lunch Break | |
| Session 03 | Track: (i) Head & Neck | |||
| Chairperson: TBD | |||
| 14:05 - 15:00 | HN Plenary (10 Mins) |
LBA2 | NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. |
| HN (5 Mins) |
6001 | Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC). | |
| HN (5 Mins) |
6008 | Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC): A multicenter phase 2 trial. | |
| HN (5 Mins) |
6012 | Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. | |
| HN (5 Mins) |
6012 | Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. | |
| HN (5 Mins) |
LBA6003 | PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial. | |
| HN (5 Mins) |
6013 | Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). | |
| HN (5 Mins) |
6015 | Phase 2 open-label study of brentuximab vedotin (BV) + pembrolizumab (pembro) in patients (pts) with treatment (tx)-naive metastatic head and neck squamous cell carcinoma (HNSCC). | |
| HN (5 Mins) |
6018 | Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II clinical trial. | |
| HN (5 Mins) |
6026 | Cetuximab plus dalpiciclib in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma. | |
| HN (5 Mins) |
6027 | Analysis of gene mutations, TMB, and PD-L1 in relation to ICI response in HNSCC. | |
| 15:00 - 15:10 | IT (10 Mins) |
Invited Talk | |
| Moderators: TBD | |||
| 15:10 - 15:30 | PD (20 Mins) |
Panel Discussion: Track: (i) Head & Neck | |
| 15:30 - 15:40 | IS (10 Mins) |
Industry Session by TBD: Topic TBD | |
| 15:40 - 15:55 | (15 MINS) | TEA BREAK | |
| GBR - 2 | ||||
|---|---|---|---|---|
| 08:00 - 10:00 | Pre Conference Workshop - 2 | Inside the Cell: Exploring the Power of Molecular Biology | ||
| Hall - 3 | |||
|---|---|---|---|
| Session 08 | Tracks: (i) Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant | (ii) Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia | (iii) Hematologic Malignancies—Plasma Cell Dyscrasia | |||
| Chairperson: TBD | |||
| 14:05 - 14:55 | HLM - LMSA PLENARY (10 Mins) |
LBA3 | Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). |
| HLM - LMSA (5 Mins) |
6502 | Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study. | |
| HLM - LMSA (5 Mins) |
6504 | An all-oral regimen of decitabine-cedazuridine (DEC-C) plus venetoclax (VEN) in patients (pts) with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts. | |
| HLM - LMSA (5 Mins) |
7000 | Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial. | |
| HLM - LMSA (5 Mins) |
7011 | SEQUOIA 5-year follow-up in arm C: Frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) | |
| HLM - LMSA (5 Mins) |
7015 | Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO. | |
| HLM - LMSA (5 Mins) |
7500 | MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial. | |
| HLM - LMSA (5 Mins) |
7506 | Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study. | |
| HLM - LMSA (5 Mins) |
7507 | Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). | |
| Moderators: TBD | Panelists | ||
| 15:05 - 15:35 | PD (30 Mins) |
Panel Discussion: Track: (i) Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant | (ii) Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia | (iii) Hematologic Malignancies-Plasma Cell Dyscrasia | |
| 15:05 - 15:35 | IS (30 Mins) |
Industry Session by TBD: Topic TBD | |
| HALL - 4 | ||||
|---|---|---|---|---|
| 09:00 - 17:00 | Focus Session 1 | Onco-Pathology | ||
| HALL - 5 | ||||
|---|---|---|---|---|
| 09:00 - 13:00 | Focus Session 2 | Onco Palliative | ||
| 14:00 - 17:00 | Focus Session 3 | Regenerative Medicine | ||
| HALL - 6 | ||||
|---|---|---|---|---|
| 09:00 - 14:00 | Focus Session 4 | Onco Pharma; Genomics & Precision Oncology | ||
| 14:00 - 17:00 | Focus Session 5 | Speech & swallow | ||
| SESSION HIGHLIGHTS | |||
|---|---|---|---|
| Time in Hrs (IST) | Track Code | Topics and Session Tracks | |
| GBR - 1 | |||
| 08:00 - 10:00 | Pre Conference Workshop - 3 | Emerging Technologies in Oncology: The Role of Artificial Intelligence. | |
| 10:00 - 11:20 | Scientific Session | Tracks: Gastrointestinal Cancer | |
| 11:45 - 13:05 | Scientific Session | Track: Lung Cancer | |
| 13:45 - 15:05 | Scientific Session | Track: Genitourinary Cancer | |
| 15:15 - 16:15 | Scientific Session | Track: Gynecologic Cancer | |
| Session 04 | Tracks: (i) Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary (ii) Gastrointestinal Cancer - Colorectal and Anal |
||||
|---|---|---|---|---|
| Chairperson: TBD | ||||
| Time in Hrs (IST) | Track Code | Paper ID | Topic | |
| 10:00 - 10:50 | GI PLENARY (10 Mins) |
LBA4 | Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). | |
| GI (5 Mins) |
4000 | Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577. | ||
| GI (5 Mins) |
LBA4002 | Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable / metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY Gastric 04 study. | ||
| GI (5 Mins) |
LBA4005 | PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC). | ||
| GI (5 Mins) |
LBA1 | Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). | ||
| GI (5 Mins) |
3505 | Perioperative systemic therapy for resectable colorectal peritoneal metastases: A multicenter randomized phase 3 trial (CAIRO6). | ||
| GI (5 Mins) |
LBA3500 | First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses. | ||
| GI (5 Mins) |
TBD | |||
| 10:50 - 11:00 | IT (5 Mins) |
Invited Talk | ||
| Moderators: TBD | ||||
| 11:00 - 11:20 | PD (20 Mins) |
Panel Discussion: Tracks: (i) Gastrointestinal CancerGastroesophageal, Pancreatic, and Hepatobiliary | (ii) Gastrointestinal Cancer - Colorectal and Anal | ||
| 11:20 - 11:30 | IS (10 Mins) |
Industry Session by TBD: Topic TBD | ||
| 11:30 – 11:45 | (15 Mins) | TEA BREAK | ||
| Session 05 | Tracks: (i) Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | (ii) Lung Cancer—Non-Small Cell Metastatic | ||||
| Chairperson: TBD | ||||
| 11:45 - 12:35 | LC PLENARY (10 Mins) |
8001 | Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. | |
| LC (5 Mins) |
8006 | Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. | ||
| LC (5 Mins) |
LBA8008 | Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis (PA) of the phase 3 DeLLphi-304 trial. | ||
| LC (5 Mins) |
LBA8000 | Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816. | ||
| LC (5 Mins) |
8503 | Efficacy of zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior platinum-based chemotherapy with or without amivantamab. | ||
| LC (5 Mins) |
8506 | Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. | ||
| LC (5 Mins) |
LBA8505 | Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study | ||
| LC (5 Mins) |
8500 | First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. | ||
| LC (5 Mins) |
TBD | |||
| 12:35 - 12:45 | IT (5 Mins) |
Invited Talk | ||
| Moderators: TBD | ||||
| 12:45 - 13:05 | PD (20 Mins) |
Panel Discussion: Tracks: (i) Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers | (ii) Lung Cancer-Non-Small Cell Metastatic | 13:05 - 13:15 | IS (10 Mins) |
Industry Session by TBD: Topic TBD |
| 13:15 – 13:45 | (30 Mins) | LUNCH BREAK | ||
| Session 06 | Tracks: (i) Genitourinary Cancer—Kidney and Bladder | (ii) Genitourinary Cancer—Prostate, Testicular, and Penile | ||||
| Chairperson: TBD | ||||
| 13:45 - 14:35 | GU (5 Mins) |
4500 | Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial. | |
| GU (5 Mins) |
4503 | Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. | ||
| GU (5 Mins) |
4505 | Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. | ||
| GU (5 Mins) |
4514 | Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). | ||
| GU (5 Mins) |
4517 | Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Event-free survival (EFS) subgroup analyses based on diseastage from the CREST study. | ||
| GU (5 Mins) |
5001 | Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE | ||
| GU (5 Mins) |
LBA5006 | Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. | ||
| GU (5 Mins) |
5002 | Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry. | ||
| GU (5 Mins) |
5003 | Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials. | ||
| GU (5 Mins) |
5007 | A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis. | ||
| 14:35 - 14:45 | IT (10 Mins) |
Invited Talk | ||
| Moderators: TBD | ||||
| 14:45 - 15:05 | PD (20 Mins) |
Panel Discussion: Track: Genitourinary Cancer | ||
| 15:05 - 15:15 | IS (10 Mins) |
Industry Session by TBD: Topic TBD | ||
| Session 07 | Tracks: (i) Gynecologic Cancer | ||||
| Chairperson: TBD | ||||
| 15:15 - 16:05 | GY (5 Mins) |
LBA5500 | TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7). | |
| GY (5 Mins) |
LBA5504 | Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. | ||
| GY (5 Mins) |
5510 | Nimotuzumab combined with chemotherapy in the first-line treatment for patients with stage IVB, recurrent or persistent cervical squamous cell carcinoma: A multi-center, randomized, double-blind, and controlled study. | ||
| GY (5 Mins) |
LBA5501 | Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial. | ||
| GY (5 Mins) |
5502 | Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses. | ||
| GY (5 Mins) |
5531 | A real-world analysis of the effectiveness of pembrolizumab by type of associated treatment in patients with metastatic cervical cancer: Added value of bevacizumab. | ||
| GY (5 Mins) |
5546 | Development and validation of a proteo-metabolic panel for detection of asymptomatic ovarian cancer with minimal serum sample requirements: A multi-center prospective study. | ||
| GY (5 Mins) |
5583 | Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advancedstage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. | ||
| GY (5 Mins) |
5554 | Final analysis of SCORES, a phase III randomized, double-blinded, placebocontrolled study of suvemcitug combined with chemotherapy for platinumresistant ovarian cancer. | ||
| GY (5 Mins) |
LBA5507 | ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). | ||
| 16:05 - 16:15 | IT (10 Mins) |
Invited Talk | ||
| Moderators: TBD | ||||
| 16:15 - 16:35 | PD (20 Mins) |
Panel Discussion: Track: Gynecologic Cancer | ||
| 16:35 - 16:45 | IS (10 Mins) |
Industry Session by TBD: Topic TBD | ||
| SESSION HIGHLIGHTS | |||
|---|---|---|---|
| Time in Hrs (IST) | Track Code | Topics and Session Tracks | |
| HALL - 3 | |||
| 09:00 - 13:00 | ASCO Poster | Award Poster Presentation - Best of ASCO, Bengaluru | |
| 15:15 - 16:35 | Scientific Session | Track: Developmental Therapeutics | |
| Session 09 | Tracks: (i) Developmental Therapeutics - Immunotherapy (ii) Developmental Therapeutics - Molecularly Targeted Agents and TumorBiology | |||
|---|---|---|---|
| Chairperson: TBD | |||
| Time in Hrs (IST) | Track Code | Paper ID | Topic |
| 15:15 - 15:45 | DT-I (5 Mins) |
2501 | First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors. |
| DT-I (5 Mins) |
2513 | Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy. | |
| DT-I (5 Mins) |
2511 | Safety and efficacy of immune checkpoint inhibitors in solid organ transplant recipients: A systematic review and individual patient data meta-analysis. | |
| DT-I (5 Mins) |
3001 | Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations. | |
| DT-I (5 Mins) |
3002 | Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC). | |
| DT-I (5 Mins) |
3006 | Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. | |
| 15:45 - 15:55 | IT (10 Mins) |
Invited Talk | |
| Moderators: TBD | |||
| 15:55 - 16:15 | PD (30 Mins) |
Panel Discussion: Track: (i) Developmental Therapeutics - Immunotherapy | (ii) Developmental Therapeutics - Molecularly Targeted Agents and Tumor Biology | |
| 16:15 - 16:35 | IS (10 Mins) |
Industry Session by TBD: Topic TBD | |
| HALL - 4 | ||||
|---|---|---|---|---|
| 09:00 - 17:00 | Focus Session 6 | Yoga | ||
| HALL - 5 | ||||
|---|---|---|---|---|
| 10:00 - 17:00 | Focus Session 7 | Research Methodolgy | ||
| HALL - 6 | ||||
|---|---|---|---|---|
| 09:00 - 14:00 | TBD | TBD | ||
Copyright© 2025 Designed & Developed by GHA Conferences